Evidence map›Paper›PMID 34768993›Full record

ArticleInternational journal of molecular sciences2021

Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.

Anna Pawłowska, Agnieszka Kwiatkowska, Dorota Suszczyk, Agata Chudzik, Rafał Tarkowski, Bartłomiej Barczyński, Jan Kotarski, Iwona Wertel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Immunotherapy in Ovarian Cancer.Archivum immunologiae et therapiae experimentalis · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anna PawłowskaIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.
Agnieszka KwiatkowskaIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.
Dorota SuszczykIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.
Agata ChudzikIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.
Rafał TarkowskiI Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-081 Lublin, Poland.
Bartłomiej BarczyńskiI Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-081 Lublin, Poland.ORCID 0000-0002-0455-0371
Jan KotarskiI Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-081 Lublin, Poland.
Iwona WertelIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, 20-093 Lublin, Poland.
Medical University of Lublin · PL

Funding

Medical University of Lublin, the Ministry of Science and Higher Education DS124, DS120Operational Program Development of Eastern Poland 2007-2013, Priority Axis I Modern Economy, Operations I.3 Innovation Promotion 'The equipment of innovative laboratories doing research of new medicines used in the therapy of civilization and neoplastic diseases'
6 · The paper itself

Abstract

The latest literature demonstrates the predominant role of the programmed cell death axis (PD-1/PD-L1/PD-L2) in ovarian cancer (OC) pathogenesis. However, data concerning this issue is ambiguous. Our research aimed to evaluate the clinical importance of PD-L1/PD-L2 expression in OC environments. We evaluated the role of PD-L1/PD-L2 in OC patients (

Indexed as

AdultAgedAged, 80 and overAntigen-Presenting CellsAscitic FluidB7-H1 AntigenCarcinoma, Ovarian EpithelialDendritic CellsFemaleHumansMiddle AgedOvarian NeoplasmsPrognosisProgrammed Cell Death 1 Ligand 2 ProteinTumor MicroenvironmentYoung AdultB7-H1 AntigenCD274 protein, humanPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 Proteinimmune suppressionimmunotherapyovarian cancerprogrammed cell death pathwaytumor microenvironment

Identifiers

PMID34768993
PMCPMC8583913
OpenAlexW3208699201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.